Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Glenmark files phase I trial application with MHPRA for GRC-15300

Jan. 26, 2009

FDA approves Geron's IND for phase I clinical trial of GRNOPC-1 in spinal cord injury

Jan. 26, 2009

Cladribine significantly reduced relapse rate of MS in phase III pivotal trial

Jan. 26, 2009

Fenobam safe, affects behavior in patients with Fragile X syndrome

Jan. 26, 2009

Solvay claims novel cannabinoid CB1 receptor agonists for use as analgesic agents

Jan. 26, 2009

Novartis launches Extavia for multiple sclerosis

Jan. 23, 2009

Phase III data support use of NGX-4010 in postherpetic neuralgia

Jan. 23, 2009

Neurologix initiates phase II clinical trial of gene transfer therapy for Parkinson's disease

Jan. 23, 2009

Novel calcitonin gene-related peptide (CGRP) receptor antagonists disclosed by Merck & Co.

Jan. 23, 2009

Vitamin effect on homocystine levels does not affect Abeta levels in stroke patients

Jan. 22, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.